Resources

I-MAK’s team has spent the last decade increasing transparency on patents, innovation, and access.

Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind

Worldwide, 71 million people are infected with hepatitis C virus (HCV), which, without treatment, can lead to liver failure or hepatocellular carcinoma. HCV co-infection increases liver- and AIDS-related morbidity and mortality among HIV-positive people, despite ART. A 12-week course of HCV direct-acting antivirals (DAAs) usually cures HCV – regardless of HIV status. However, patents and…

Commentaries 9 Apr 2018

Join us to stay updated
and help make lifesaving medicines accessible to all